Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Demetriou, Georgia
FATIMA, NCT02917005: PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer	Recruiting	2	160	RoW	Palbociclib, Ibrance, Exemestane, Aromasine, Goserelin, Zoladex	Hamdy A. Azim	Metastatic Breast Cancer	12/21	12/23
GALAXIES LUNG-201, NCT05565378 / 2021-005115-32: A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer	Recruiting	2	340	Europe, Japan, US, RoW	Pembrolizumab, Dostarlimab, GSK4057190, Belrestotug, EOS884448, GSK4428859A, Nelistotug, GSK6097608	GlaxoSmithKline, iTeos Therapeutics	Lung Cancer, Non-Small Cell	10/25	10/28
NCT03763604: Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer	Approved for marketing	N/A		Europe, Canada, RoW	Abemaciclib, LY2835219	Eli Lilly and Company	Metastatic Breast Cancer